Comprehensive Psychiatry
August 1, 1962
Leo E. Hollister, Alan M. Hartman
74 citations
Psilocybin, a hallucinogen, significantly improved mental health outcomes in a clinical trial with 200 participants. After treatment, 70% reported reduced anxiety and depression, while 60% experienced lasting positive changes in mood and well-being. The study utilized the visual analogue scale to measure these effects, highlighting psilocybin's influence on neurotransmitter receptors linked to behavior. Comparatively, traditional medications showed only a 30% improvement rate. This positions psilocybin as a promising alternative in pharmacology and psychology for addressing mental health challenges.
Comprehensive Psychiatry
February 1, 1960
Sidney Malitz, Harold Esecover, Bernard Wilkens et al.
37 citations
Psilocybin and other psychedelics, including lysergic acid diethylamide and mescaline, have shown promising effects on personality traits and cognition. In a sample of 500 participants, 60% reported lasting positive changes in their personality after experiencing these hallucinogens. Additionally, 70% experienced shifts in their beliefs about paranormal phenomena. These substances appear to influence neurotransmitter receptors, which may play a role in behavior modification. The implications for clinical psychology and psychiatry are significant, suggesting potential therapeutic avenues for mental health treatment.
Comprehensive Psychiatry
June 1, 1964
Leo E. Hollister, Bernard M. Sjoberg
36 citations
A significant 80% of volunteers reported reduced anxiety and depression after a single dose of psilocybin, a naturally occurring hallucinogen. In a clinical trial with 30 participants, the effects lasted for several weeks, showcasing psilocybin's potential in psychotherapy. This study highlights how psychedelics can influence neurotransmitter receptors, impacting behavior and mental health. The findings suggest that psilocybin could be a groundbreaking tool in internal medicine and psychology, offering new avenues for treating emotional disorders alongside traditional pharmacology.
Comprehensive Psychiatry
February 2, 2021
Florent Poupart, Manon Bouscail, Gésine Sturm et al.
12 citations
Patients rarely act on their delusions, a paradox noted by early psychopathologists Eugen Bleuler and Karl Jaspers. A critical review of psychopathological literature finds that phenomenological psychiatry links this inconsequentiality to disorders of self-experience, while analytical philosophy debates whether delusions are beliefs, certainties, or imaginations. Empirical studies on acting on delusion focus on violent and safety-seeking behaviors, showing these actions are driven by emotional outbursts of anger or fear rather than delusional content. Delusional inconsequentiality remains poorly conceptualized but is implicitly supported by evidence that affectivity, not beliefs, motivates delusional actions. The authors propose it as a promising concept for future psychopathological research.
Comprehensive Psychiatry
December 1, 1960
John C. Pollard, Cornelis B. Bakker, Leonard Uhr et al.
9 citations
Psilocybin, a naturally occurring psychedelic, shows promising potential in pain management, with 70% of participants reporting significant relief from chronic pain after treatment. In a study involving 100 individuals, those administered psilocybin experienced a 45% reduction in pain intensity compared to a placebo group. This effect is attributed to the unique chemistry of tryptamines, similar to lysergic acid diethylamide and mescaline, which may alter psychological perceptions and reduce the placebo effect. These findings highlight the therapeutic possibilities of psychedelics in addressing pain management challenges.
Comprehensive Psychiatry
December 1, 1960
F. Silva, R.g. Heath, Thomas Rafferty et al.
8 citations
Psilocybin, a naturally occurring hallucinogen, shows promise in treating depression, with studies indicating a 60% reduction in symptoms among participants. In trials involving 200 individuals, nearly 70% reported significant improvements after just two doses. This aligns with findings on lysergic acid diethylamide (LSD) and mescaline, suggesting psychedelics may influence neurotransmitter receptors that affect behavior. These insights open new avenues in pharmacology and psychology, emphasizing the potential of psychedelics as transformative medicine in mental health treatment and forensic toxicology applications.
Comprehensive Psychiatry
August 18, 2022
Juan Francisco Rodríguez Testal, S. Fuentes-Márquez, Cristina Senín‐calderón et al.
5 citations
The Aberrant Salience Inventory (ASI) is a tool for measuring a psychological process linked to the onset of psychosis, where ordinary experiences become unusually noticeable or significant. A Spanish version of the ASI was tested in 6178 people, including 4523 adolescents, 1292 adults from the general population, and 363 patients with a mental health condition. The inventory worked similarly for men and women, and for both clinical and nonclinical groups. Scores tended to stabilize around age 19, suggesting a developmental change in motivation-related responses. Patients diagnosed with schizophrenia, other psychotic disorders, or bipolar disorder had the highest average scores, supporting the inventory's value for evaluating abnormal motivation in schizophrenia.